SLAM-family Receptors Come of Age As a Potential Molecular Target in Cancer Immunotherapy

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 May 30

PMID 37251372

Authors

Pooya Farhangnia

Shamim Mollazadeh Ghomi

Shabnam Mollazadehghomi

Hamid Nickho

Mahzad Akbarpour

Ali-Akbar Delbandi

Affiliations

Soon will be listed here.

Abstract

The signaling lymphocytic activation molecule (SLAM) family receptors were discovered in immune cells for the first time. The SLAM-family receptors are a significant player in cytotoxicity, humoral immune responses, autoimmune diseases, lymphocyte development, cell survival, and cell adhesion. There is growing evidence that SLAM-family receptors have been involved in cancer progression and heralded as a novel immune checkpoint on T cells. Previous studies have reported the role of SLAMs in tumor immunity in various cancers, including chronic lymphocytic leukemia, lymphoma, multiple myeloma, acute myeloid leukemia, hepatocellular carcinoma, head and neck squamous cell carcinoma, pancreas, lung, and melanoma. Evidence has deciphered that the SLAM-family receptors may be targeted for cancer immunotherapy. However, our understanding in this regard is not complete. This review will discuss the role of SLAM-family receptors in cancer immunotherapy. It will also provide an update on recent advances in SLAM-based targeted immunotherapies.

Citing Articles

Tumor-infiltrating myeloid cells; mechanisms, functional significance, and targeting in cancer therapy.

Toghraie F, Bayat M, Hosseini M, Ramezani A Cell Oncol (Dordr). 2025; .

PMID: 39998754 DOI: 10.1007/s13402-025-01051-y.

Imaging of biphasic signalosomes constructed by checkpoint receptor 2B4 in conventional and chimeric antigen receptor-T cells.

Matsushima R, Wakamatsu E, Machiyama H, Nishi W, Yoshida Y, Nishikawa T iScience. 2025; 28(1):111669.

PMID: 39886466 PMC: 11780131. DOI: 10.1016/j.isci.2024.111669.

Myeloid cells meet CD8 T cell exhaustion in cancer: What, why and how.

Zhai Y, Liang X, Deng M Chin J Cancer Res. 2025; 36(6):616-651.

PMID: 39802897 PMC: 11724180. DOI: 10.21147/j.issn.1000-9604.2024.06.04.

Structure, Attachment and Transmembrane Internalisation of Peste Des Petits Ruminants Virus.

Zou H, Niu Z, Cheng P, Wu C, Li W, Luo G Vet Med Sci. 2024; 11(1):e70182.

PMID: 39739994 PMC: 11683676. DOI: 10.1002/vms3.70182.

Research on the influence of radiotherapy-related genes on immune infiltration, immunotherapy response and prognosis in melanoma based on multi-omics.

Shi Y, Zhao W, Ding Y, Ge X, Ju M Front Immunol. 2024; 15:1467098.

PMID: 39687627 PMC: 11647020. DOI: 10.3389/fimmu.2024.1467098.

References

Lee K, McNerney M, Stepp S, Mathew P, Schatzle J, Bennett M . 2B4 acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells. J Exp Med. 2004; 199(9):1245-54. PMC: 2211902. DOI: 10.1084/jem.20031989. View

Chatterjee M, Hedrich C, Rauen T, Ioannidis C, Terhorst C, Tsokos G . CD3-T cell receptor co-stimulation through SLAMF3 and SLAMF6 receptors enhances RORγt recruitment to the IL17A promoter in human T lymphocytes. J Biol Chem. 2012; 287(45):38168-77. PMC: 3488086. DOI: 10.1074/jbc.M112.415067. View

Yusuf I, Kageyama R, Monticelli L, Johnston R, DiToro D, Hansen K . Germinal center T follicular helper cell IL-4 production is dependent on signaling lymphocytic activation molecule receptor (CD150). J Immunol. 2010; 185(1):190-202. PMC: 2913439. DOI: 10.4049/jimmunol.0903505. View

Mateos M, Granell M, Oriol A, Martinez-Lopez J, Blade J, Hernandez M . Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. Br J Haematol. 2016; 175(3):448-456. DOI: 10.1111/bjh.14263. View

Kumaresan P, Lai W, Chuang S, Bennett M, Mathew P . CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol. 2002; 39(1-2):1-8. DOI: 10.1016/s0161-5890(02)00094-9. View

Gordiienko I, Shlapatska L, Kholodniuk V, Sklyarenko L, Gluzman D, Clark E . The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling. PLoS One. 2017; 12(10):e0185940. PMC: 5628907. DOI: 10.1371/journal.pone.0185940. View

Jakubowiak A, Offidani M, Pegourie B, Rubia J, Garderet L, Laribi K . Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016; 127(23):2833-40. PMC: 4900953. DOI: 10.1182/blood-2016-01-694604. View

Sever L, Radomir L, Stirm K, Wiener A, Schottlender N, Lewinsky H . SLAMF9 regulates pDC homeostasis and function in health and disease. Proc Natl Acad Sci U S A. 2019; 116(33):16489-16496. PMC: 6697803. DOI: 10.1073/pnas.1900079116. View

Marom A, Barak A, Kramer M, Lewinsky H, Binsky-Ehrenreich I, Cohen S . CD84 mediates CLL-microenvironment interactions. Oncogene. 2016; 36(5):628-638. DOI: 10.1038/onc.2016.238. View

10.

Wang X, Walter M, Urak R, Weng L, Huynh C, Lim L . Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Clin Cancer Res. 2017; 24(1):106-119. PMC: 5991104. DOI: 10.1158/1078-0432.CCR-17-0344. View

11.

De Calisto J, Wang N, Wang G, Yigit B, Engel P, Terhorst C . SAP-Dependent and -Independent Regulation of Innate T Cell Development Involving SLAMF Receptors. Front Immunol. 2014; 5:186. PMC: 4005954. DOI: 10.3389/fimmu.2014.00186. View

12.

Yigit B, Halibozek P, Chen S, OKeeffe M, Arnason J, Avigan D . A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells. Oncotarget. 2016; 7(18):26346-60. PMC: 5041984. DOI: 10.18632/oncotarget.8378. View

13.

Brown M, Boles K, van der Merwe P, Kumar V, Mathew P, Barclay A . 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J Exp Med. 1998; 188(11):2083-90. PMC: 2212392. DOI: 10.1084/jem.188.11.2083. View

14.

Yurchenko M, Kashuba E, Shlapatska L, Sivkovich S, Sidorenko S . The role of CD150-SH2D1A association in CD150 signaling in Hodgkin's lymphoma cell lines. Exp Oncol. 2005; 27(1):24-30. View

15.

Wang Z, Guan W, Wang M, Chen J, Zhang L, Xiao Y . AML1-ETO inhibits acute myeloid leukemia immune escape by CD48. Leuk Lymphoma. 2020; 62(4):937-943. DOI: 10.1080/10428194.2020.1849680. View

16.

Tatsuo H, Ono N, Tanaka K, Yanagi Y . SLAM (CDw150) is a cellular receptor for measles virus. Nature. 2000; 406(6798):893-7. DOI: 10.1038/35022579. View

17.

Sandrin M, Henning M, Lo M, Baker E, Sutherland G, McKenzie I . Isolation and characterization of cDNA clones for Humly9: the human homologue of mouse Ly9. Immunogenetics. 1996; 43(1-2):13-9. DOI: 10.1007/BF00186599. View

18.

Morandi B, Costa R, Falco M, Parolini S, De Maria A, Ratto G . Distinctive lack of CD48 expression in subsets of human dendritic cells tunes NK cell activation. J Immunol. 2005; 175(6):3690-7. DOI: 10.4049/jimmunol.175.6.3690. View

19.

Zelle-Rieser C, Thangavadivel S, Biedermann R, Brunner A, Stoitzner P, Willenbacher E . T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol. 2016; 9(1):116. PMC: 5093947. DOI: 10.1186/s13045-016-0345-3. View

20.

von Wenserski L, Schultheiss C, Bolz S, Schliffke S, Simnica D, Willscher E . SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2. Leukemia. 2020; 35(4):1073-1086. PMC: 8024197. DOI: 10.1038/s41375-020-01025-z. View